Mumbai, January 20, 2026: Immunoadoptive Cell Therapy Private Limited (ImmunoACT), India’s pioneering cell and gene therapy company, today announced an exclusive license and supply agreement with Cipla Limited (BSE: 500087; NSE: CIPLA EQ; hereafter referred to as “Cipla”), through its step-down subsidiary Medpro Pharmaceutica. Under the agreement, Cipla will commercialize talicabtagene autoleucel, India’s first indigenously developed CAR-T cell therapy, in South Africa, the People’s Democratic Republic of Algeria, and the Kingdom of Morocco.
This landmark collaboration reinforces ImmunoACT’s mission to innovate and make cell and gene therapies accessible and affordable worldwide, particularly in underserved regions. Talicabtagene autoleucel is an autologous anti-CD19 CAR-T cell therapy, indicated for the treatment of adult and adolescent patients with relapsed or refractory B-cell Non-Hodgkin’s Lymphoma (B-NHL) and B-cell Acute Lymphoblastic Leukemia (B-ALL) who have not responded to, or have relapsed following, standard lines of therapy.
The therapy has already been administered to over 500 patients in India as of December 2025. As per the terms of the agreement, ImmunoACT will manufacture the product in India, while Cipla will lead commercialization across the licensed African territories, hereby expanding access of this revolutionary new treatment to markets currently with unmet needs.
Commenting on the partnership, Dr. Rahul Purwar, Founder & Chairman, ImmunoACT, and Professor at the Indian Institute of Technology (IIT) Bombay, said: “Our mission has always been to innovate and make cell and gene therapies accessible and affordable to address the vast unmet need worldwide. This strategic partnership with Cipla will help accelerate our efforts and offer patients with B-cell malignancies a meaningful opportunity for durable remission through our CAR-T platform.”
Umang Vohra, Managing Director and Global Chief Executive Officer, Cipla Limited, said: “Our collaboration with ImmunoACT reflects Cipla’s vision of harnessing cutting-edge science to deliver transformative and affordable therapies, particularly in emerging markets where unmet medical needs remain significant.”
Paul Miller, Chief Executive Officer, Cipla Africa, added: “We are proud to be at the forefront of introducing CAR-T cell therapy to Africa. This partnership strengthens our oncology portfolio and reinforces Cipla’s mission of making next-generation therapies accessible to patients globally.”
About CAR-T Cell Therapy CAR-T (Chimeric Antigen Receptor T-cell) therapy is an advanced form of immunotherapy in which a patient’s own T-cells are genetically modified to recognize and eliminate cancer cells with high specificity.
About ImmunoACT ImmunoACT (Immunoadoptive Cell Therapy Private Limited) is India’s first fully integrated CAR-T cell therapy company, developing and manufacturing accessible, affordable gene-modified cell therapies for blood cancers and solid tumors. Its lead product, NexCAR19™, developed in collaboration with IIT Bombay and Tata Memorial Centre, is India’s first commercially approved CAR-T cell therapy and has transformed outcomes in relapsed/refractory B-cell malignancies. ImmunoACT’s pipeline includes a BCMA-directed CAR-T therapy for multiple myeloma and several solid tumor CAR-T programs under development. The company is expanding global access through strategic international partnerships. For more information, visit www.immunoact.com